{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 22,
  "pageCount": 36,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_disclosure",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes extensive footnotes citing regulatory documents and investor call transcripts.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/22",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-22",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In order to receive FDA approval, Chinook would need to demonstrate that atrasentan is clinically superior to sparsentan; if it does not, sparsentan retains exclusivity for the next seven years.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-ece42cc021e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "In an investors' call on May 10, Chinook executives suggested that atrasentan was more likely to demonstrate a favorable hepatotoxicity risk profile than sparsentan.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dcb5670-d11f-4bab-9ac1-949efdc1bf3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Sparsentan is occupying atrasentan's lane, and meanwhile, the FDA has asked Chinook to delay readout of its top-line data... In order to receive FDA approval, Chinook would need to demonstrate that atrasentan is clinically superior to sparsentan.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41b690af-1c61-4969-9e13-97e287dcc8cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Atrasentan is chemically and mechanistically similar to rival developer Travere Therapeutics' (NASDAQ: TVTX) sparsentan, which has already received accelerated and exclusive orphan drug approval for reduction of proteinuria in immunoglobulin A nephropathy (IgAN).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b9acf64-5a59-4377-b9cf-cde45b13b7a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "…launching without a liver REMS would certainly be a potential area of differentiation [from sparsentan], and we do think we have a strong scientific rationale to support that for atrasentan… So we'll begin that dialogue. It's likely ultimately to be a review issue. — Chinook Company Conference Presentation, May 10.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-f0cf4d471683",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.8,
        "x": 0.1,
        "y": 0.5
      },
      "kind": "source-note",
      "text": "Footnotes 109-119 detailing regulatory sources and company presentations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d643a6c-e0ad-4c38-951a-e49bc8fa987b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.1,
        "y": 0.08
      },
      "kind": "title",
      "text": "Sparsentan: Likely Blocking Atrasentan from the IgAN Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76f6a381-f403-41a2-b5b7-76e044040e1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "ae001a79-4c58-47ad-8a20-18a8d16fed11",
      "evidence": "The slide explicitly addresses the counter-argument regarding hepatotoxicity risk profiles.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}